Goodwin assisted Metagenomi on the matter. Preclinical biotech Metagenomi went public on the Nasdaq under the ticker “MGX”, raising $94 million by offering 6.25 million shares...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
You must be a Standard 1 Year member to access this content.
Fenwick & West and Wilson Sonsini Goodrich & Rosati advised Metagenomi on the deal while Gunderson Dettmer represented PFM Health Sciences. Metagenomi, a genetic medicines company...
You must be a Standard 1 Year member to access this content.
Fenwick & West and Wilson Sonsini Goodrich & Rosati represented Metagenomi on the deal. Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation...
You must be a Standard 1 Year member to access this content.
